#genfit

To follow today … GENFIT – Boursorama

[ad_1]

(AOF) – On Monday, Genfit jumped 7.73% to 14.63 euros to sign the largest increase in the SBF 120. The French biotech announced results from a study demonstrating that NIS4, non-invasive diagnostic tool developed for the diagnosis of nonalcoholic steatohepatitis (Nash), performed better than other non-invasive tools in patients with type 2 diabetes. These results were presented on…

Lyft and six other companies went public in March. Here’s the full list

The IPO market is slowly catching up with seven companies hitting the stock markets in March. The most notable IPO among them happened late on March 28, when ride-hailing firm Lyft (LYFT) priced its shares at $72. It was one of the most touted IPOs of this year, the biggest by valuation since Alibaba (BABA) IPO in 2014.

When Lyft announced its IPO in December, it was looking at a price range of…

Nasdaq Welcomes GENFIT S.A. (Nasdaq: GNFT) to The Nasdaq Stock Market

Nasdaq Welcomes GENFIT S.A. (Nasdaq: GNFT) to The Nasdaq Stock Market – World News Report – EIN News <meta name="generator" conten... Nasdaq Search Results

What is NASH and which biotech firms are vying for the first-mover status

NASH, or Nonalcoholic steatohepatitis, is undeniably a golden goose in the pharma space. The biggest corporate attraction towards this liver disorder is the fact that there are currently no treatments available in the market, and therefore, whoever manages a breakthrough in the clinical trials would grab the first-mover advantage.

It also nullifies the requirement during phase 3 trials to prove…

NASH drug developer Genfit plans $132-million US IPO, to list on Nasdaq

France-based biopharmaceutical firm Genfit (EPA: GNFT) has launched a global offering of its American Depository Shares and ordinary shares to raise around $132 million. The company also intends to list as “GNFT” on the Nasdaq Global Market.

An SEC filing by the company indicated last week that the main purpose of the offering is to take forward the development of treatment for non-alcoholic…